Q3 Earnings Estimate for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright issued their Q3 2027 EPS estimates for shares of Harmony Biosciences in a research note issued to investors on Thursday, April 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will earn $1.26 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.33 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2027 earnings at $1.49 EPS.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business had revenue of $243.78 million during the quarter, compared to the consensus estimate of $240.04 million. During the same quarter last year, the company earned $0.85 EPS. Harmony Biosciences’s revenue for the quarter was up 21.1% on a year-over-year basis.

A number of other equities research analysts have also recently commented on HRMY. Mizuho set a $50.00 target price on shares of Harmony Biosciences in a research note on Thursday, February 19th. Bank of America decreased their target price on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research note on Wednesday, February 25th. Truist Financial cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. UBS Group decreased their target price on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research note on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Harmony Biosciences currently has a consensus rating of “Hold” and an average price target of $42.67.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $30.80 on Monday. Harmony Biosciences has a twelve month low of $25.52 and a twelve month high of $40.87. The stock has a market capitalization of $1.78 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 0.42 and a beta of 0.89. The firm’s 50 day moving average price is $29.12 and its 200-day moving average price is $32.79. The company has a quick ratio of 3.58, a current ratio of 3.60 and a debt-to-equity ratio of 0.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Public Sector Pension Investment Board grew its holdings in shares of Harmony Biosciences by 41.6% in the third quarter. Public Sector Pension Investment Board now owns 185,803 shares of the company’s stock valued at $5,121,000 after purchasing an additional 54,605 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Harmony Biosciences by 39.3% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 234,779 shares of the company’s stock worth $6,471,000 after buying an additional 66,236 shares during the period. American Century Companies Inc. boosted its stake in Harmony Biosciences by 11.2% during the third quarter. American Century Companies Inc. now owns 1,669,565 shares of the company’s stock worth $46,013,000 after buying an additional 168,145 shares during the period. LSV Asset Management boosted its stake in Harmony Biosciences by 7.1% during the third quarter. LSV Asset Management now owns 1,594,893 shares of the company’s stock worth $43,955,000 after buying an additional 106,391 shares during the period. Finally, Paradiem LLC purchased a new position in Harmony Biosciences during the third quarter worth $724,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.